Critiquing: Wikipedia – Burzynski Clinic

[1] – Wikipedia, claims:
——————————————————————
“There is a scientific consensus that antineoplaston therapy is unproven and of little promise in treating cancer””
——————————————————————
“… a Mayo Clinic study found no benefit from antineoplaston treatment.[1]””
——————————————————————
“The Memorial Sloan-Kettering Cancer Center has stated: “Bottom Line: There is no clear evidence to support the anticancer effects of antineoplastons in humans.”[1]””
——————————————————————
Interestingly, the above 1st claim by “Wikipedia” does NOT provide any specific citation(s), reference(s), or link(s) to support this claim
——————————————————————
[2] – 2/1999 – What “Wikipedia” does NOT advise the reader about the 2nd and 3rd claims, is that the conclusion of the study was:

“Although we could not confirm any tumor regression in patients in this study, the small sample size precludes definitive conclusions about treatment efficacy
——————————————————————
[3] – 6/1999 – Wikipedia also does NOT point out that Burzynski replied to the 2/1999 publication, that:

[A] – Study tested dosing regimen known to be ineffective

[B] – Dosages of A10 and AS2–1 used in study were meant for treatment of single small lesion (<5 cm)

5 of the 6 evaluable patients had either multiple nodules or tumors larger than 5 cm

[C] – As the provider of A10 and AS2–1, I strongly suggested to the National Cancer Institute (NCI) that these patients receive a much higher dose, consistent with greater tumor load

[D] – Study was closed when I insisted the NCI either increase the dosage or inform the patients that the drug manufacturer believed that the treatment was unlikely to be effective at the dosages being used
(letter to Dr M. Sznol, NCI, on 4/20/1995)

[E] – Review of clinical data in the article by Buckner et al proves validity of my position

[F] – Study patients had extremely low plasma antineoplaston levels

My phase 2 study dosage regimen produced plasma phenylacetylglutamine (PG) levels 35 times greater, phenylacetylisoglutamine (isoPG) levels 53 times greater, and phenylacetate (PN) levels 2 times greater than those reported by Buckner et a1 [1]

[G] – Clinical outcomes reported by Buckner et al, based on inadequate dosage schedule, differ dramatically from my phase 2 studies in which higher dosage regimen was used

[H] – They reported no tumor regression

In contrast, in 1 of my ongoing studies on protocol BT-9, 4 of 8 evaluable patients with astrocytoma had objective responses [2]

[I] – Difference in outcomes primarily due to difference in dosage schedules

[J] – Another factor that may have caused a lack of response in the study by Buckner et al is duration of treatment was too brief

Almost all patients in their study received treatment for less than 30 days

1 patient received only 9 days of treatment

Current studies indicate objective tumor responses usually observed after 3 months of therapy

Additional 8 months of treatment usually needed to obtain maximal therapeutic effect

[K] – Ambiguities in response evaluation and analysis in article by Buckner et al

In.2 patients, tumor necrosis attributed to “radio-necrosis”

Interpretation’s clouded by fact antineoplaston-induced necrosis can be indistinguishable from radionecrosis

[L] – Analysis by Buckner et al could’ve highlighted 2 patients with recurrent glioblastoma who survived for more than 1 year

This is of interest because patients typically have life expectancy of 3 to 6 months

[M] – At time of the study by Buckner et al, the sponsor, NCI, decided against higher dosing regimen I proposed and closed the study

Study used dosing regimen known to be ineffective
======================================
[4] – 10/4/1991 – Five doctors (3 from the Cancer Therapy Evaluation Branch (CTEP); including the Head of the Quality Assurance and Compliance Section, Regulatory Affairs Branch, Cancer Therapy Evaluation Program, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, and 2 invited consultants; including one from the National Institutes of Health (NIH) Clinical Center) visited the offices of Dr. Stanislaw R. Burzynski
——————————————————————
[5] – 10/31/1991 – Michael A. Friedman, M.D. Associate Director, Cancer Therapy Evaluation Program (CTEP), Department of Health &Human Services, National Institutes of Health, National Cancer Institute, sent a one page Memorandum to Bruce A. Chabner, M.D., Director, Division of Cancer Treatment, which stated, in part:

“I thought you would be interested in this for several reasons:”

“3. Antineoplastons deserve a closer look”

“It turns out that the agents are well defined, pure chemical entities
=======================================
=======================================
“The human brain tumor responses are real”

20130911-102213.jpg
=======================================
[6] – 11/15/1991 – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, sent a 7 page letter to Decision Network, which stated, in part, on page one:
=======================================
=======================================
“It was the opinion of the site visit team that antitumor activity was documented in this best case series … “

20130911-122216.jpg
=======================================
[7] – 12/2/91 – NCI (National Cancer Institute), Decision Network Report on Antineoplastons, states in part, on page 11:
=======================================
=======================================
“The site visit team determined that antitumor activity was documented in this best case series … “

20130911-134634.jpg
=======================================
[8] – CANCER FACTS
National Cancer Institute • National Institutes of Health Department of Health and Human Services, Antineoplastons, pg. 1

=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “

20130911-094155.jpg
=======================================
[9] – Page 1 of 6, BlueCross BlueShield of Alabama, Antineoplaston Cancer Therapy, Policy #: 280, Category: Medicine, states, in part, on page 2 of 6:

Key Points:
=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “
=======================================
=======================================
[10] – ANTINEOPLASTON THERAPY, HS-183, pg. 2
=======================================
=======================================
“After the reviewers found some evidence of antitumor activity … “
=======================================
=======================================
These facts indicate to me that Wikipedia’s claim about “antineoplastons”, is “debatable”

Maybe they should have learned how to use the Freedom of Information Act (FOIA)
=======================================
REFERENCES:
=======================================
[1]
——————————————————————
http://en.wikipedia.org/wiki/Burzynski_Clinic
——————————————————————
http://en.m.wikipedia.org/wiki/Burzynski_Clinic
——————————————————————
Antineoplastons, Memorial Sloan-Kettering Cancer Center
======================================
[2] – 2/1999 – A10 and AS2-1 – Phase II
Mayo Clinic Proceedings
http://www.ncbi.nlm.nih.gov/m/pubmed/10069350
Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent Glioma

Material & Methods:

Patients received escalating doses of A10 and AS2-1 by multiple intermittent intravenous injections with use of portable programmable pump to the target daily dose of 1.0 g/kg for A10 and of 0.4 g/kg for AS2-1

Mean steady-state plasma concentrations of phenylacetate & phenylacetylglutamine after escalation to the target doses of A10 and AS2-1 were 177 +/-101 ug/mL & 302 +/- 102 ug/mL, respectively

Results:

9 patients were treated, in 6 of whom treatment response was assessable in accordance with protocol stipulations
http://linkinghub.elsevier.com/retrieve/pii/S0025-6196(11)63835-4
Comment in Jun; 74 (6): 641-2
http://www.sciencedirect.com/science/article/pii/S0025619611638354
Mayo Clin Proc 74(2):9 (1999), PMID .10069350
http://www.mayoclinicproceedings.org/article/S0025-6196(11)63835-4/fulltext
DOI: 10.4065/74.2.137
http://download.journals.elsevierhealth.com/pdfs/journals/0025-6196/PIIS0025619611638354.pdf
Mayo Clin Proc 1999; 74: 137–145
http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2796.2003.01098.x/full
Mayo Clin Proc 1999; 74: 137–45
http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2796.2003.01098.x/references
J C Buckner, M G Malkin, E Reed, T L Cascino, J M Reid, M M Ames, W P Tong, S Lim, W D Figg
http://onlinelibrary.wiley.com/store/10.1046/j.1365-2796.2003.01098.x/asset/j.1365-2796.2003.01098.x.pdf?v=1&t=hbs6xce2&s=3423e3cd1955667e8e8cdf33323faf0bd85b6a29
Department of Oncology, Mayo Clinic Rochester, Minnesota USA
http://onlinelibrary.wiley.com/store/10.1046/j.1365-2796.2003.01098.x/asset/j.1365-2796.2003.01098.x.pdf?v=1&t=hbrndkdf&s=e0af2d3bfb13841852d92a839d3a4932a5f4bb48
======================================
[3] – 6/1999 – A10 and AS2-1
http://www.ncbi.nlm.nih.gov/pubmed/10377942
Efficacy of antineoplastons A10 and AS2-1
http://www.ncbi.nlm.nih.gov/m/pubmed/10377942
S R Burzynski
Mayo Clin Proc 74 (6): 641-2 (1999),
Mayo Clin Proc. 1999 Jun; 74 (6): 641-2
http://linkinghub.elsevier.com/retrieve/pii/S0025-6196(11)64143-8
Comment on
Mayo Clin Proc. 1999 Feb; 74 (2): 137-45 PMID .10377942
http://www.mayoclinicproceedings.org/article/S0025-6196(11)64143-8/fulltext
Mayo Clin Proc. 1999
http://download.journals.elsevierhealth.com/pdfs/journals/0025-6196/PIIS0025619611641438.pdf
Comment on
Mayo Clinic Proc. 1999; 74: 641–642 (letter)
http://linkinghub.elsevier.com/retrieve/pii/S0025-6196(11)64143-8
Mayo Clin Proc
74 (6): 641-2
http://download.journals.elsevierhealth.com/pdfs/journals/0025-6196/PIIS0025619611641438.pdf
Mayo Clin Proc 74 (6): 1 (1999),
Elsevier Ltd.
DOI: 10.4065/74.6.641
1999 – A10 and AS2-1 – Mayo
Buckner, Reid, & Malkin
Mayo Clin Proc 74 (6): 2 (1999),
Elsevier Ltd.
DOI: 10.4065/74.6.641-a
http://www.mayoclinicproceedings.org/article/S0025-6196(11)64144-X/fulltext
Mayo Clinic Proceedings
74(6):2 1999 Elsevier Ltd.
http://download.journals.elsevierhealth.com/pdfs/journals/0025-6196/PIIS002561961164144X.pdf
=======================================
[8]
——————————————————————
http://www.emory.edu/KomenEd/PDF/Treatment/Antineoplastons.pdf
=======================================
[9]
——————————————————————
https://www.bcbsal.org/providers/policies/final/280.pdf
=======================================
[10]
——————————————————————
https://www.wellcare.com/WCAssets/corporate/assets/HS183_Antineoplaston_Therapy.pdf
=======================================

Critiquing: Memorial Sloan-Kettering Cancer Center (MSKCC)

[1]Memorial Sloan-Kettering Cancer Center (MSKCC), How It Works,, claims:

”Bottom Line: There is no clear evidence to support the anticancer effects of antineoplastons in humans”
——————————————————————
Interestingly, the above “Bottom Line” does NOT provide any specific citation(s), reference(s), or link(s) to support this claim
——————————————————————
[2] – 10/4/1991 – Five doctors (3 from the Cancer Therapy Evaluation Branch (CTEP); including the Head of the Quality Assurance and Compliance Section, Regulatory Affairs Branch, Cancer Therapy Evaluation Program, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, and 2 invited consultants; including one from the National Institutes of Health (NIH) Clinical Center) visited the offices of Dr. Stanislaw R. Burzynski
——————————————————————
[3] – 10/31/1991 – Michael A. Friedman, M.D. Associate Director, Cancer Therapy Evaluation Program (CTEP), Department of Health &Human Services, National Institutes of Health, National Cancer Institute, sent a one page Memorandum to Bruce A. Chabner, M.D., Director, Division of Cancer Treatment, which stated, in part:

“I thought you would be interested in this for several reasons:”

“3. Antineoplastons deserve a closer look”

“It turns out that the agents are well defined, pure chemical entities
=======================================
=======================================
“The human brain tumor responses are real”

20130911-102213.jpg
=======================================
[4] – 11/15/1991 – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, sent a 7 page letter to Decision Network, which stated, in part, on page one:
=======================================
=======================================
“It was the opinion of the site visit team that antitumor activity was documented in this best case series … “

20130911-122216.jpg
=======================================
[5] – 12/2/91 – NCI (National Cancer Institute), Decision Network Report on Antineoplastons, states in part, on page 11:
=======================================
=======================================
“The site visit team determined that antitumor activity was documented in this best case series … “

20130911-134634.jpg
=======================================
[6] – CANCER FACTS
National Cancer Institute • National Institutes of Health Department of Health and Human Services, Antineoplastons, pg. 1

=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “

20130911-094155.jpg
=======================================
[7] – Page 1 of 6, BlueCross BlueShield of Alabama, Antineoplaston Cancer Therapy, Policy #: 280, Category: Medicine, states, in part, on page 2 of 6:

Key Points:
=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “
=======================================
=======================================
[8] – ANTINEOPLASTON THERAPY, HS-183, pg. 2
=======================================
=======================================
“After the reviewers found some evidence of antitumor activity … “
=======================================
=======================================
These facts indicate to me that Memorial Sloan-Kettering Cancer Center’s (MSKCC) claim about “antineoplastons”, is “debatable”

Maybe they should have learned how to use the Freedom of Information Act (FOIA)
=======================================
REFERENCES:
=======================================
[1]
——————————————————————
http://www.mskcc.org/cancer-care/herb/antineoplaston
=======================================
[6]
——————————————————————
http://www.emory.edu/KomenEd/PDF/Treatment/Antineoplastons.pdf
=======================================
[7]
——————————————————————
https://www.bcbsal.org/providers/policies/final/280.pdf
=======================================
[8]
——————————————————————
https://www.wellcare.com/WCAssets/corporate/assets/HS183_Antineoplaston_Therapy.pdf
=======================================

Critiquing: American Cancer Society – Antineoplaston Therapy

[1] – The American Cancer Society Antineoplaston Therapy Overview claims:
=====================================
=====================================
” In other words, there is no convincing evidence showing that antineoplastons actually work
=====================================
=====================================
====================================
Interestingly, the above Overview does NOT provide any specific citation(s), reference(s), or link(s) to support this claim
——————————————————————
[2] – 10/4/1991 – Five doctors (3 from the Cancer Therapy Evaluation Branch (CTEP); including the Head of the Quality Assurance and Compliance Section, Regulatory Affairs Branch, Cancer Therapy Evaluation Program, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, and 2 invited consultants; including one from the National Institutes of Health (NIH) Clinical Center) visited the offices of Dr. Stanislaw R. Burzynski
——————————————————————
[3] – 10/31/1991 – Michael A. Friedman, M.D. Associate Director, Cancer Therapy Evaluation Program (CTEP), Department of Health &Human Services, National Institutes of Health, National Cancer Institute, sent a one page Memorandum to Bruce A. Chabner, M.D., Director, Division of Cancer Treatment, which stated, in part:

“I thought you would be interested in this for several reasons:”

“3. Antineoplastons deserve a closer look”

“It turns out that the agents are well defined, pure chemical entities
=======================================
=======================================
“The human brain tumor responses are real”

20130911-102213.jpg
=======================================
[4] – 11/15/1991 – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, sent a 7 page letter to Decision Network, which stated, in part, on page one:
=======================================
=======================================
“It was the opinion of the site visit team that antitumor activity was documented in this best case series … “

20130911-122216.jpg
=======================================
[5] – 12/2/91 – NCI (National Cancer Institute), Decision Network Report on Antineoplastons, states in part, on page 11:
=======================================
=======================================
“The site visit team determined that antitumor activity was documented in this best case series … “

20130911-134634.jpg
=======================================
[6] – CANCER FACTS
National Cancer Institute • National Institutes of Health Department of Health and Human Services, Antineoplastons, pg. 1

=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “

20130911-094155.jpg
=======================================
[7] – Page 1 of 6, BlueCross BlueShield of Alabama, Antineoplaston Cancer Therapy, Policy #: 280, Category: Medicine, states, in part, on page 2 of 6:

Key Points:
=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “
=======================================
=======================================
[8] – ANTINEOPLASTON THERAPY, HS-183, pg. 2
=======================================
=======================================
“After the reviewers found some evidence of antitumor activity … “
=======================================
=======================================
These facts indicate to me that the American Cancer Society’s claim about “antineoplastons”, is “debatable”

Maybe they should have learned how to use the Freedom of Information Act (FOIA)
=======================================
REFERENCES:
=======================================
[1]
——————————————————————
http://m.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternativemedicine/pharmacologicalandbiologicaltreatment/antineoplaston-therapy
=======================================
[6]
——————————————————————
http://www.emory.edu/KomenEd/PDF/Treatment/Antineoplastons.pdf
=======================================
[7]
——————————————————————
https://www.bcbsal.org/providers/policies/final/280.pdf
=======================================
[8]
——————————————————————
https://www.wellcare.com/WCAssets/corporate/assets/HS183_Antineoplaston_Therapy.pdf
=======================================

Critiquing: Quackwatch: Stanislaw Burzynski and “Antineoplastons” – Saul Green, Ph.D.

[1] – Quackwatch has this article which claims, in part:

“Tracing the biochemistry involved in Burzynski’s synthesis of antineoplastons shows that the substances are without value for cancer treatment”

Burzynski has never demonstrated that A-2.1 (PA) or “soluble A-10″ (PA and PAG) are effective against cancer or that tumor cells from patients treated with these antineoplastons have been “normalized.””

“Tests of antineoplastons at the National Cancer Institute have never been positive”

“The drug company Sigma-Tau Pharmaceuticals could not duplicate Burzynski’s claims for AS-2.1 and A-10

“The Japanese National Cancer Institute has reported that antineoplastons did not work in their studies”

“These facts indicate to me that Burzynski’s claims that his “antineoplastons” are effective against cancer are not credible”

About the Author

Dr. Green (1925-2007) was a biochemist who did cancer research at Memorial Sloan-Kettering Cancer Center for 23 years

He consulted on scientific methodology and had a special interest in unproven methods

This article was adapted from his presentation at the American Association for Clinical Chemistry Symposium in Atlanta in July 1997

This page was revised on January 19, 2013
====================================
Interestingly, the above article does NOT provide any specific citation(s), reference(s), or link(s) to support any of these claims
——————————————————————
[2] – 10/4/1991 – Five doctors (3 from the Cancer Therapy Evaluation Branch (CTEP); including the Head of the Quality Assurance and Compliance Section, Regulatory Affairs Branch, Cancer Therapy Evaluation Program, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, and 2 invited consultants; including one from the National Institutes of Health (NIH) Clinical Center) visited the offices of Dr. Stanislaw R. Burzynski
——————————————————————
[3] – 10/31/1991 – Michael A. Friedman, M.D. Associate Director, Cancer Therapy Evaluation Program (CTEP), Department of Health &Human Services, National Institutes of Health, National Cancer Institute, sent a one page Memorandum to Bruce A. Chabner, M.D., Director, Division of Cancer Treatment, which stated, in part:

“I thought you would be interested in this for several reasons:”

“3. Antineoplastons deserve a closer look”

“It turns out that the agents are well defined, pure chemical entities
=======================================
=======================================
“The human brain tumor responses are real”

20130911-102213.jpg
=======================================
[4] – 11/15/1991 – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, sent a 7 page letter to Decision Network, which stated, in part, on page one:
=======================================
=======================================
“It was the opinion of the site visit team that antitumor activity was documented in this best case series … “

20130911-122216.jpg
=======================================
[5] – 12/2/91 – NCI (National Cancer Institute), Decision Network Report on Antineoplastons, states in part, on page 11:
=======================================
=======================================
“The site visit team determined that antitumor activity was documented in this best case series … “

20130911-134634.jpg
=======================================
[6] – CANCER FACTS
National Cancer Institute • National Institutes of Health Department of Health and Human Services, Antineoplastons, pg. 1

=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “

20130911-094155.jpg
=======================================
[7] – Page 1 of 6, BlueCross BlueShield of Alabama, Antineoplaston Cancer Therapy, Policy #: 280, Category: Medicine, states, in part, on page 2 of 6:

Key Points:
=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “
=======================================
=======================================
[8] – ANTINEOPLASTON THERAPY, HS-183, pg. 2
=======================================
=======================================
“After the reviewers found some evidence of antitumor activity … “
=======================================
=======================================
These facts indicate to me that Quackwatch, and Saul Green’s claims about “antineoplastons”, are “not credible”

Maybe they should have learned how to use the Freedom of Information Act (FOIA)
=======================================
REFERENCES:
=======================================
[1] – Stanislaw Burzynski and “Antineoplastons”
Saul Green, Ph.D.

——————————————————————
http://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/burzynski1.html
=======================================
[6]
——————————————————————
http://www.emory.edu/KomenEd/PDF/Treatment/Antineoplastons.pdf
=======================================
[7]
——————————————————————
https://www.bcbsal.org/providers/policies/final/280.pdf
=======================================
[8]
——————————————————————
https://www.wellcare.com/WCAssets/corporate/assets/HS183_Antineoplaston_Therapy.pdf
=======================================

Critiquing: Dr. Michael A. Friedman, Dr. Mark G. Malkin, Dr. Mario Sznol, Robert B. Lanman, Memorial Sloan-Kettering Cancer Center, Mayo Clinic, Department of Health & Human Services (HHS), Public Health Service, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Center (NCI) at the National Institutes of Health (NIH), Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies

One of Dr. David H. “Orac” Gorski’s “Oracolytes,” a wooshipper of their Lord and Master, Lord Frackonis AstroidZeneca posted this “gem” of a comment on National Geographic’s (#NatGeo) scienceblogs . com/Insolence
——————————————————————
[A] – 4/30/2013 – #98 – Krebiozen – May.28, 2013

BTW, DJT appears to have completely unraveled on his blog, calling Orac, “a self-proclaimed “cancer researcher” ” making many other blatantly libelous statements, ranting on, and on, and on. He is clearly unwell. If anyone who knows him personally happens to read this, please get him some professional help.
——————————————————————
What does Krebiozen think Dr. David H. “Orac” Gorski is going to do since I’ve been giving the “big reveal” to some of his lies, misdirection, misinformation, and disinformation ?

Sue me for telling the truth about his lies ?
——————————————————————
[B] – 12/.5/2012 – Gorski posted:

“Indeed, one could argue that that’s why the FDA and the NCI couldn’t work with him” (Burzynski)

“They didn’t know him when they agreed to work with him in the 1990s, but as they worked with him over the course of a few years they learned his true nature, leading to an inevitable schism, which taught the NCI a lesson about the consequences of dealing with pseudoscientists”
——————————————————————
Does Gorski provide a “citation” for his claim ?

no !

Does he provide a “reference” ?

No !!

A “link” ?

NO !!!

So where did Gorski come up with this unsubstantiated claim ?

Well, it seems that Gorski has cited The Cancer Letter before without attribution
——————————————————————
[C] – 9/25/1998 – “Stanislaw Burzynski, a Polish-trained physician who initially produced antineoplastons by extracting them from human urine”
——————————————————————
[D] – 2/19/2013 – Now where have I seen a questionable statement like this before ?
——————————————————————
[E] – 1/14/2013 – Gorski posted: “As you might recall, antineoplastons are chemicals that Burzynski found in the urine of cancer patients … “
——————————————————————
[C] – 9/25/1998 – The Cancer Letter indicated that a:

trial of antineoplastons, coordinated by NCI, began at Memorial Sloan-Kettering Cancer Center, the Mayo Clinic, and the NIH Clinical Center
——————————————————————
And that the
——————————————————————
“trial, which tested Burzynski’s drug in advanced recurrent malignant glioma, accrued 9 patients and was aborted as a result of a dispute

“The dispute generated a stack of mutually recriminating memos, in which Burzynski accused the investigators of attempting to scuttle the trial, while NCI officials responded with requests that Burzynski provide the data that would back his accusations
——————————————————————
[F] – 6/23/2013 – Gorski has already proved that he does NOT have what it takes to provide the answers for the National Cancer Institute (NCI) at the National Institutes of Health (NIH)
——————————————————————
[G] – 3/30/2013

NO, Dr. Gorski, you have NOT “deconstructed his” evidence “in depth before”

Burzynski: Cancer Is Serious Business (Part I) consists of the documentary; which covered some of this, as well as the documents on the movie web-site, which you have NOT “deconstructed … in depth before”, since you
“cherry-picked” what you reviewed

Allow me
=======================================
[1] – 10/4/1991 – Five doctors (3 from the Cancer Therapy Evaluation Branch (CTEP); including the Head of the Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Department of Health & Human Services (HHS), Public Health Service, National Institutes of Health (NIH), National Cancer Institute (NCI), and 2 invited consultants; including one from the National Institutes of Health (NIH) Clinical Center) visited the offices of Dr. Stanislaw R. Burzynski
=======================================
[2] – 10/30/1991 – Dorothy K. Macfarlane, M.D., Head, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Department of Health & Human Services (HHS), Public Health Service, National Institutes of Health (NIH), National Cancer Institute (NCI) sent a 1 page letter and 5 page Memorandum to Burzynski
=======================================
[3] – 10/30/1991 – Dorothy K. Macfarlane, M.D., Head, Quality Assurance and Compliance Section, Regulatory Affairs Branch (RAB), Cancer Therapy Evaluation Program (CTEP), Department of Health & Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), sent the 5 page Memorandum re: Review of Brain Tumor Cases Treated With Antineoplastons to 6 doctors
=======================================
======================================
[4] – 10/31/1991 – Michael A. Friedman, M.D. Associate Director, Cancer Therapy Evaluation Program (CTEP), Department of Health & Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), sent a one page Memorandum to Bruce A. Chabner, M.D., Director, Division of Cancer Treatment, which stated, in part:

“I thought you would be interested in this for several reasons:”

“3. Antineoplastons deserve a closer look”

“It turns out that the agents are well defined, pure chemical entities
=======================================
=======================================
“The human brain tumor responses are real”

20130911-102213.jpg
=======================================
[5] – 11/15/1991 – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health & Human Services (HHS), Public Health Service, National Institutes of Health (NIH), National Cancer Institute (NCI), sent a 7 page letter re: Antineoplaston to Decision Network, which stated, in part, on page one:
=======================================
=======================================
“It was the opinion of the site visit team that antitumor activity was documented in this best case series … “

20130911-122216.jpg
=======================================
[6] – 12/2/1991 – NCI (National Cancer Institute), Decision Network Report on Antineoplastons, states in part, on page 11:
=======================================
=======================================
“The site visit team determined that antitumor activity was documented in this best case series … “

20130911-134634.jpg
=======================================
[00] – 1991 (12/1991) – the National Cancer Institute (NCI) initiated phase II clinical trials of A10 and AS2-1 (antineoplastons)
=======================================
[7] – 10/20/1993 – Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institutes (NCI), Department of Health and Human Services (HHS), National Institutes of Health (NIH) sent a 4 page letter to Burzynski, which had on page 4:
=======================================
======================================
“If you are unable or unwilling to provide the antineoplastons in the near future, we will pursue alternative sources to procure the drug or its active components, and will proceed with a clinical development plan to determine whether these chemicals have activity and are beneficial for patients

20130916-121522.jpg
=======================================
[8] – 10/26/1993 – Burzynski sent a 5 page letter to Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institutes (NCI), National Institutes of Health (NIH), which had on page 5
=======================================
======================================
“Your final statements that you are ready to proceed with the treatment with Antineoplastons without our participation caught me by surprise”

“It is hard to imagine that a Federal employee would consider patent infringement, thus infringing on the patent rights of thousands of our shareholders”

20130916-123059.jpg
——————————————————————
Dr. Michael A. Friedman, please take time away from being a “member of the Nominating Committee” and “director” at Forbes (#Forbes)
——————————————————————
http://www.forbes.com/profile/michael-friedman/
——————————————————————
to let us know how you planned to:

“pursue alternative sources to procure the drug (Antineoplaston) or its active components”

when Burzynski has a patent on some of “its active components” ?

I’m sure your position has nothing to do with the “hack piece” Forbes did on Burzynski where they censored my comments [000]
=======================================
[9] – 11/2/1993 – Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), Department of Health & Human Services, Public Health Services, National Institutes of Health (NIH), sent a 3 page letter to Burzynski, which had on page 3
=======================================
======================================
“Finally, if even after modifying these studies in accordance with your stated wishes, you are unwilling to supply the antineoplaston materials, please inform me as quickly as possible”

“We will then seek alternative sources of this family of molecules for proper clinical evaluation”

20130916-161534.jpg

20130916-161909.jpg

20130916-162248.jpg
Dr. Michael A. Friedman, please take time away from planning your retirement from “City of Hope”
——————————————————————
http://m.prnewswire.com/news-releases/city-of-hope-names-robert-stone-as-new-chief-executive-officer-192239551.html
——————————————————————
to let us know how you planned to:

” … then seek alternative sources of this (Antineoplaston) family of molecules for proper clinical evaluation”, when Burzynski has a patent on some of “this family of molecules”?
=======================================
[10] – 1/18/1994 – Proposal for Clinical Investigation [2 pgs.]

Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Advanced Recurrent Malignant Astrocytomas

N.C.I. Protocol # T93-0078

Pg. 2

1.0 Protocol Summary – Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Advanced Recurrent Malignant Astrocytomas

1.1 Patient Eligibility

k) Patients with tumors > 5 cm in diameter, multifocal tumors, or with leptomeningeal or with systemic metastases are excluded

1.2 Pretreatment Evaluation

1.3 Treatment Plan

20130915-192906.jpg

20130915-193228.jpg
=======================================
[11] – 3/23/1994 – Mario Sznol, M.D., Head, Biologics Evaluation Section, Investigational Drug Branch, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), Department of Health & Human Services (HHS), Public Health Services, National Institutes of Health (NIH), National Cancer Institutes (NCI) sent a 2 page letter to Burzynski requesting to:

1. Lower the Karnofsky performance status (KPS) from 70 to 60

2. Raise the tumor size restriction from 5 cm or less to 8 cm or less

3. Drop the exclusion of multifocal tumors and leptomeningeal spread

20130916-182546.jpg

20130916-183050.jpg
=======================================
[12] – 4/19/1994 – Burzynski sent a 2 page letter to Mario Sznol, M.D., Head, Biologics Evaluation Section, Investigational Drug Branch, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), Department of Health & Human Services (HHS), Public Health Services, National Institutes of Health (NIH), National Cancer Institutes (NCI), the it was his opinion that cancer patients with larger tumors should:

1. NOT be included in the protocol intended for patients with smaller tumors receiving less antineoplastons

2. Cancer patients with larger tumors should be accepted in a separate protocol for larger tumors using larger doses of antineoplastons if the existing protocol showed promise

20130916-181845.jpg

20130916-183656.jpg
=======================================
[13] – 1/31/1995 – Mark G. Malkin, M.D. sent a one page letter to John L. Lewis, M.D., Chairman, Institutional Review Board (IRB), Memorial Sloan-Kettering Cancer Center (MSKCC) re: T93-0078, RE: Protocol # 93-105, indicating that the National Cancer Institute (NCI) had changed the protocol by:

1. Lowering the Karnofsky Performance Status Score (KPS) from 70% to 60%

2. Removing the exclusion criteria so that there was “no exclusion based on tumor size, multifocality, or leptomeningeal or systemic metastases”

20130916-202002.jpg
Dr. Mark G. Malkin, the Institutional Principal Investigator, Department of Neurology, Memorial Sloan-Kettering Cancer Center (MSKCC) who sent this letter to Dr. John L. Lewis, the Protocol Chairman, can you take time from your position at the Medical College of Wisconsin
——————————————————————
http://www.mcw.edu/neurology/faculty/MarkMalkin.htm
——————————————————————
and explain why Burzynski was NOT copied on this letter since you knew from his 4/19/1994 response [12] to your 3/23/1994 letter [11] that he did NOT agree to changing the protocol?
=======================================
[14] – 3/29/1995 – Burzynski sent a 2 page letter to Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), National Institutes of Health (NIH), advising him that he had learned that the protocol had been changed without his knowledge or concurrence by:

1. Lowering the Karnofsky Performance Status score (KPS) from 70% to 60%

2. Changing the eligibility criteria from tumors 5 cm or less to patients with tumors measuring over 5 cm in diameter, multiple tumors, or with leptomeningeal spread or systemic metastases

Dr. Michael A. Friedman, please take time from your Non-Executive Director appointment at Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business
——————————————————————
http://www.smith-nephew.com/news-and-media/news/michael-a-friedman-md-appointed-non-executive-director/
——————————————————————
and advise why these changes where made to the protocol, when your 3 page letter of 11/2/1993 [9] to Burzynski, advised:

Pg. 1

“[W]e will accede to all the modifications that you have stipulated”

“The changes to made to the protocol are as follows:”

1. “The dose and schedule will be modified exactly as your require”

Pg. 2

5. “The eligibility criteria will be modified to accept only patients with a Karnofsky performance status of 70-100%

20130916-215525.jpg

20130916-215909.jpg
=======================================
[15] – 4/3/1995 – Mario Sznol, M.D., Department of Health and Human Services (HHS), Public Health Services, National Institutes of Health (NIH), National Cancer Institutes (NCI) sent a 2 page letter to Burzynski for Dr. Michael A. Friedman in response to Burzynski’s 3/29/1995 letter [14] advising:

“At the investigator’s request, the amendments to modify the eligibility restrictions for size of tumor, number of tumors, and leptomeningeal spread, and to allow entry of patients with KPS of 60, have been approved

as if the National Cancer Institute (NCI) had NOT already changed the protocol 1/31/1995 [13]

20130916-234004.jpg

20130916-235141.jpg
=======================================
[16] – 4/20/1995 – Burzynski sent a 3 page letter to Mario Sznol, M.D., Department of Health and Human Services (HHS), National Institutes of Health (NIH)

20130917-000811.jpg

20130917-001541.jpg

20130917-002052.jpg
=======================================
[17] – 4/26/1995 –

20130917-010419.jpg

20130917-010958.jpg
=======================================
[18] – 5/16/1995 – Burzynski sent a 3 page letter to Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), National Institutes of Health (NIH)

20130917-003756.jpg

20130917-004513.jpg

20130917-005059.jpg
=======================================
[19] – 6/6/1995 – Michael A. Friedman, M.D., Associate Director, Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), Department of Health & Human Services (HHS), Public Health Service, National Institutes of Health (NIH), sent a 3 page letter to Burzynski

20130917-012249.jpg

20130917-012808.jpg

20130917-013241.jpg
=======================================
[0000] – 7/27/1995 pg. A17 The Washington Post

In Absentia, Regulators Put on Trial by Critics

‘But researchers who have tried to duplicate Burzynski’s success have been frustrated, said Michael A. Friedman, associate director of the National Cancer Institute’s cancer therapy evaluation program in no small part because Burzynski has refused to cooperate fully”

Dr. Michael A. Friedman
——————————————————————
https://tulane.edu/presidentialsearch/michael-friedman.cfm
——————————————————————
I’m sure that Dr. David H. Gorski a/k/a “Orac” would have something to say about you commenting on a clinical trial before the final results were published, but what do you mean by:

“Burzynski has refused to cooperate fully” ?
=======================================
[20] – 8/18/1995 – CancerNet from the National Cancer Institute (NCI) [2 Pgs.]
Date Last Modified 10/1995

20130917-014814.jpg

20130917-015200.jpg
=======================================
[21] – 8/23/1995 – Robert B. Lanman, National Institutes of Health (NIH) Legal Advisor sent a one page letter to Richard A. Jaffe, which advised, in part:

“The NCI does not possess any individual patient records to provide to Dr. Burzynski”

20130917-020236.jpg
=======================================
[22] – 9/19/1995 – Dr. Michael A. Friedman sent a 2 page letter to Burzynski, which advised, in part, on page 2:

“We have no individual patient records in our possession in addition to the Theradex reports”

20130917-021234.jpg

20130917-021547.jpg
=======================================
[23] – 10/5/1995 – Robert B. Lanman, National Institutes of Health (NIH) Legal Advisor sent a one page letter to Richard A. Jaffe, which advised, in part:

“With regard to the portion of the medical record which you forwarded, the stamp does indicate that the patient was seen at the National Institutes of Health’s Clinical Center”

“We have learned that 2 patients were enrolled in the Sloan-Kettering study through the Clinical Center and hence, even though the Clinical Center did not have its own protocol, it has medical records for those 2 individuals”

20130917-022524.jpg
=======================================
[24] – 10/27/1995 – Burzynski sent a 7 page letter to Richard Klausner, M.D., Director, National Cancer Institute (NCI), National Institutes of Health (NIH)

20130917-043710.jpg

20130917-044107.jpg

20130917-044527.jpg
=======================================
[00] – 1995 (12/1995) – the National Cancer Institute (NCI) initiated phase II clinical trials of A10 and AS2-1 (antineoplastons) from 12/1991 – 12/1995
=======================================
[25] – 1/15/1998 – Robert J. Waldbillig, Ph.D.

Pharmacokinetics of Antineoplaston A10 and AS2-1 in Patients with Neoplastic Disease (2 pgs.)

20130917-035626.jpg

20130917-040010.jpg
Pg. 2

Translated into ug/mL from page 22 of 1998 FDA report on ANP

Plasma Antineoplaston Levels in Patients During Treatment

Name of Antineoplaston Ingredient
PG
IsoPG
PN

Plasma Levels (ug/mL)

Mayo Clinic (MC)
302
14 to 35
177

Burzynski
11088
2376
476

Ratio
Burzynski / MC
36 x higher
67-169 x higher
2.7 x higher

=======================================
[26] – 2/1999 Volume 74 Number 2 [3 Pgs. – Pg. 137]

Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent Glioma

Jan C. Buckner, M.D. (Mayo) Dept.Oncology
Mark G. Malkin, M.D.
Eddie Reed, M.D.
Terrence L. Cascino, M.D.
Joel M. Reid, Ph.D.
Matthew M. Ames, Ph.D.
William P.Y. Tong, Ph.D.
Silam Lam, Ph.D.
William D. Figg, Pharm.D.

Patients with
anaplastic astrocytoma

and
glioblastoma multiforme

20130917-042229.jpg

20130917-042604.jpg

20130917-043019.jpg
=======================================
National Cancer Center (NCI) at the National Institutes of Health (NIH), I do believe this is some of “the data that would back his” (Burzynski’s) “accusations”

Dr. David H. Gorski a/k/a “Orac”, enjoy !
======================================
REFERENCES [A – G]:
======================================
[A] – 4/30/2013 – Eric Merola and Stanislaw Burzynski’s secret weapon against The Skeptics™: Fabio Lanzoni (I kid you not)
——————————————————————
http://scienceblogs.com/insolence/2013/04/30/eric-merola-stanislaw-burzynskis-secret-weapon-against-the-skeptics-fabio-lanzoni/
======================================
[B] – 12/5/2012 – Stanislaw Burzynski: On the arrogance of ignorance about cancer and targeted therapies
——————————————————————
http://scienceblogs.com/insolence/2012/12/05/arrogance-of-ignorance-about-cancer/
======================================
[C] – 9/25/1998 – The Antineoplaston Anomaly: How a Drug Was Used for Decades in Thousands of Patients, With No Safety, Efficacy Data
——————————————————————
http://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/burzynski2.html
——————————————————————
The Cancer Letter, Vol. 24, No. 36, Sept.25, 1998
======================================
[D] – 2/19/2013
——————————————————————
http://m.cancer.gov/topics/CAM/antineoplastons/Patient?print=1
——————————————————————
http://m.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternativemedicine/pharmacologicalandbiologicaltreatment/antineoplaston-therapy
======================================
[E] – 1/14/2013 – The story of Seán Ó’Laighin, patient of Dr. Stanislaw Burzynski
——————————————————————
http://scienceblogs.com/insolence/2013/01/14/the-story-of-sean-olaighin-patient-of-dr-stanislaw-burzynski/
======================================
[F] – 6/23/2013 – QUESTIONS the Critics and Cynics, “The Skeptics™” do NOT want to ANSWER:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/06/23/questions-the-critics-and-cynics-the-skeptics-do-not-want-to-answer/
======================================
[G] – 3/20/2013 – David Gorski (@gorskon) tweeted at 12:44pm – 30 Mar 13:
======================================
=======================================
REFERENCES:
=======================================
1] – 1991 (10/4/1991) – Site visit – Antineoplaston Cases:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/1-1991-1041991-site-visit-antineoplaston-cases/
=======================================
[2] – 1991 (10/30/1991) – Dr. Dorothy K. Macfarlane letter to Burzynski:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/2-1991-10301991-dr-dorothy-k-macfarlane-letter-to-burzynski/
=======================================
[3] – 1991 (10/30/1991) – Dr. Dorothy K. Macfarlane Memorandum – 10/4/1991 – site visit (5 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/3-1991-10301991-dr-dorothy-k-macfarlane-memorandum-1041991-site-visit-5-pgs/
=======================================
[4] – 1991 (10/31/1991) – Dr. Michael A. Friedman Memorandum to Dr. Bruce A. Chabner (1 pg.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/4-1991-10311991-dr-michael-a-friedman-memorandum-to-dr-bruce-a-chabner-1-pg/
=======================================
[5] – 1991 (11/15/1991) – Dr. Michael J. Hawkins to Decision Network:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/5-1991-11151991-dr-michael-j-hawkins-to-decision-network/
=======================================
[6] – 1991 (12/2/1991) – NCI Decision Network Report on Antineoplastons:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/6-1991-12291-nci-decision-network-report-on-antineoplastons/
=======================================
[00] – 1991 (12/1991) – Burzynski: Managing social conflict in complementary and alternative medicine research: the case of antineoplastons:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/burzynski-managing-social-conflict-in-complementary-and-alternative-medicine-research-the-case-of-antineoplastons/
=======================================
[7] – 1993 (10/20/1993) – Dr. Michael A. Friedman to Burzynski (4 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/7-1993-10201993-dr-michael-a-friedman-to-burzynski-4-pgs/
=======================================
[8] – 1993 (10/26/1993) – Burzynski to Dr. Michael A. Friedman:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/17/8-1993-10261993-burzynski-to-dr-michael-a-friedman/
=======================================
[000] – Dr. Peter A. Lipson (and / or his Censor(s)) is a Coward: Critiquing “A Film Producer, A Cancer Doctor, And Their Critics”:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/dr-peter-a-lipson-and-or-his-censors-is-a-coward-critiquing-a-film-producer-a-cancer-doctor-and-their-critics/
=======================================
[9] – 1993 (11/2/1993) – Dr. Michael A. Friedman to Burzynski:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/9-1993-1121993-dr-michael-a-friedman-to-burzynski/
=======================================
[10] – 1994 (1/18/1994) – Proposal for Clinical Investigation (2 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/10-1994-1181994-proposal-for-clinical-investigation-2-pgs/
=======================================
[11] – 1994 (3/23/1994) – Dr. Mario Sznol to Burzynski [2 pgs.]:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/11-1994-3231994-dr-mario-sznol-to-burzynski-2-pgs/
=======================================
[12] – 1994 (4/19/1994) – Burzynski to Dr. Mario Sznol [2 Pgs.]:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/12-1994-4191994-burzynski-to-dr-mario-sznol-2-pgs/
=======================================
[13] – 1995 (1/31/1995) – Dr. Mark G. Malkin to Dr. John L. Lewis (1 pg.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/13-1995-1311995-dr-mark-g-malkin-to-dr-john-l-lewis-1-pg/
=======================================
[14] – 1995 (3/29/1995) – Burzynski to Dr. Michael A. Friedman (2 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/14-1995-3291995-burzynski-to-dr-michael-a-friedman-2-pgs/
=======================================
[15] – 1995 (4/3/1995) – Dr. Mario Sznol to Burzynski:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/15-1995-431995-dr-mario-sznol-to-burzynski/
=======================================
[16] – 1995 (4/20/1995) – Burzynski to Dr. Mario Sznol;
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/16-1995-4201995-burzynski-to-dr-mario-sznol/
=======================================
[17] – 1995 (4/26/1995) (Pg. 3):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/17-1995-4261995-pg-3/
=======================================
[18] – 1995 (5/16/1995) – Burzynski to Dr. Michael A. Friedman:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/18-1995-5161995-burzynski-to-dr-michael-a-friedman/
=======================================
[19] – 1995 (6/6/1995) Dr. Michael A. Friedman to Burzynski (3 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/19-1995-661995-dr-michael-a-friedman-to-burzynski-3-pgs/
=======================================
[0000] – 7/27/1995 – 1 pg.
——————————————————————
http://legacy.library.ucsf.edu/documentStore/c/q/d/cqd59b00/Scqd59b00.pdf
——————————————————————
2 pgs.
——————————————————————
http://legacy.library.ucsf.edu/documentStore/y/i/w/yiw77d00/Syiw77d00.pdf
=======================================
[20] – 1995 (8/18/1995) – CancerNet from the National Cancer Institute (2 pgs.): CANCER FACTS
National Cancer Institute • National Institutes of Health Department of Health and Human Services, Antineoplastons, pg. 1

——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/20-1995-8181995-cancernet-from-the-national-cancer-institute-2-pgs/
=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “

20130911-094155.jpg
=======================================
=======================================
=======================================
[21] – 1995 (8/23/1995) – Robert B. Lanman to Burzynski (1 Pg.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/21-1995-8231995-robert-b-lanman-to-burzynski-1-pg/
=======================================
[22] – 1995 (9/19/1995) – Dr. Michael A. Friedman to Burzynski (2 pgs.):]
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/22-1995-9191995-dr-michael-a-friedman-to-burzynski-2-pgs/
=======================================
[23] – 1995 (10/5/1995) – Robert B. Lanman to Burzynski (1 pg.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/23-1995-1051995-robert-b-lanman-to-burzynski-1-pg/
=======================================
[24] – 1995 (10/27/1995) – Burzynski to Dr. Richard Klausner (7 pgs.):
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/18/24-1995-10271995-burzynski-to-dr-richard-klausner-7-pgs/
=======================================
=======================================

Burzynski Securities and Exchange Commission (SEC) Links

� � � � � � � � � � � � � � � � �
======================================
11/25/1997 – FORM 10-SB
http://pdf.secdatabase.com/2573/0000950110-97-001598.pdf
12/10/1997
http://www.siliconinvestor.com/readmsg.aspx?msgid=2965068
Burzynski developed
——————————————————————
6 formulations of natural Antineoplastons
——————————————————————
6 synthetic formulations of Antineoplastons
======================================
All Phase II clinical trials currently involve use of
——————————————————————
4 formulations of synthetic Antineoplastons known as
A10 and AS2-1 in capsules and injections
======================================
Company currently conducting laboratory research involving
——————————————————————
new generation of Antineoplastons A10 and AS2-1
======================================
In addition to original family of Antineoplaston compounds

(the “Parental Generation”)

Company continues development of
——————————————————————
2nd generation of Antineoplastons
======================================
In cell culture experiments
2nd generation Antineoplastons developed by Company, have been shown to be at least

——————————————————————
a thousand times more potent then
Parental Generation
======================================
Company developing
3rd generation structurally altered Antineoplaston Company believes will exhibit markedly improved anticancer activity in human cancer cell lines resistant to
Parental Generation
======================================
10/1997 only 2 clinical trials reached Milestone
——————————————————————
Clinical Trial BT-11
Clinical Trial BT-18
======================================
Clinical Trial BT-18 involving intravenous administration of
Antineoplastons A10 and AS2-1
in treatment of “mixed glioma”, a type of PMBT

3/1996 – Trial approved by FDA
results evaluated after 9 patients accrued
======================================
Another trial of Clinical Trial BT-11 involves patients with brain stem glioma
trial approved by FDA 5/1996
======================================
Clinical trials conducted by Burzynski 3/1/1996 – 2/28/1997
======================================
11/25/1997 72 Phase II clinical trials conducted pursuant to INDs filed with FDA
======================================
12/10/1997
http://www.siliconinvestor.com/readmsg.aspx?msgid=2965068
72 Phase II Clinical Trials
======================================
� � � � � � � � � � � � � � � � �
======================================
10/30/1998 (11/12/1998)
http://www.sec.gov/Archives/edgar/data/724445/0001015402-98-000442.txt
======================================
� � � � � � � � � � � � � � � � �
======================================
5/31/2000 (5/10/2001) 10QSB
http://www.sec.gov/Archives/edgar/data/724445/0000912057-01-514477.txt
72 FDA approved clinical trials
======================================
� � � � � � � � � � � � � � � � �
======================================
5/31/2001 (7/12/2001) 10QSB
http://www.sec.gov/Archives/edgar/data/724445/0000912057-01-523630.txt
72 FDA approved clinical trials
======================================
� � � � � � � � � � � � � � � � �
======================================
5/31/2002 (7/10/2002) FORM 10-QSB
http://www.sec.gov/Archives/edgar/data/724445/0000912057-02-027187.txt
72 FDA approved clinical trials
======================================
8/31/2002
http://www.sec.gov/Archives/edgar/data/724445/000091205702038660/a2091272z10qsb.txt
======================================
� � � � � � � � � � � � � � � � �
======================================
11/30/2002 (1/14/2003)
http://pdf.secdatabase.com/1129/0001047469-03-001370.pdf
72 FDA approved clinical trials
======================================
5/31/2003
http://google.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=2384291-21562-30830&SessionID=yDBMFSPZzEQ6eD7
======================================
10/15/2003-7/15/2008
http://marketbrief.com/bzyr/10qsb
======================================
� � � � � � � � � � � � � � � � �
======================================
11/10/2004
http://www.sec.gov/Archives/edgar/data/724445/000104746904033767/0001047469-04-033767.txt
� � � � � � � � � � � � � � � � �
======================================
10/15/2003-7/15/2008
http://marketbrief.com/bzyr/10qsb
======================================
11/30/2005 – For the quarterly period ended
http://edgar.secdatabase.com/1472/95012906000296/filing-main.htm
35 FDA-approved clinical trials
——————————————————————
11/30/2005
http://google.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=4132756-45428-48732&SessionID=sghhFSHpJO17En2
======================================
� � � � � � � � � � � � � � � � �
5/31/2007
http://edgar.secdatabase.com/1173/110465907054073/filing-main.htm
27 FDA-approved clinical trials
======================================
� � � � � � � � � � � � � � � � �
======================================
10/15/2003-7/15/2008
http://marketbrief.com/bzyr/10qsb
======================================
� � � � � � � � � � � � � � � � �
======================================
1/13/2009 (1/4/2011)
http://www.mystockbuddy.com/forum/archive/index.php/t-3959.html
——————————————————————
1/13/2009
http://www.sec.gov/Archives/edgar/data/724445/000110465909002283/a09-2965_1ex99d1.htm
1/13/2009 Burzynski Research Institute Gets SPA Clearance from FDA to Initiate Pivotal Phase III Trial of Combination Antineoplaston Therapy and Radiation Therapy, Study to Evaluate Children with Newly-Diagnosed Diffuse Intrinsic Brainstem Glioma

EX-99.1 4 a09-2965_1ex99d1.htm EX-99.1

Exhibit 99.1

HOUSTON, TX – 1/13/2009 –
Burzynski Research Institute, Inc. (BRI) announced it has reached agreement with U.S. Food and Drug Administration (FDA) that enables company to move forward immediately with pivotal Phase III clinical trial of combination antineoplaston therapy plus radiation therapy in patients with newly-diagnosed, diffuse, intrinsic brainstem glioma

Antineoplaston therapy (ANP) uses synthetic version of naturally occurring peptides & amino acid derivatives found in human body to target & control cancer cells without destroying normal cells

Agreement made under FDA’s Special Protocol Assessment (SPA) procedure & means design & planned analysis of Phase III study is acceptable to support regulatory submission seeking new drug approval

“We are very pleased by our agreement with the FDA to move forward with a confirmatory study on a type of tumor that has shown itself to be highly treatment resistant & challenged further by severely limited treatment options & clinical trials that could expand & discover new, efficacious therapies,” said Stanislaw R. Burzynski, M.D., Ph.D

“The SPA agreement puts antineoplaston therapy further down a straight path to regulatory approval, enabling the kind of study that should prove its merits as another option to cancer management.”

“BRI has reached this important milestone independently without financial backing from the government, & without a major pharmaceutical partner—a unique accomplishment in the oncology field

From inception, we have been committed to developing a targeted gene therapy option that is less aggressive on the body than conventional therapies & have made considerable progress on the steps mandated by the FDA to bring a new drug to a patient community & cancer type that has unmet needs.”

About Phase III study

Primary objective of randomized study is to compare overall survival of children with newly-diagnosed diffuse intrinsic brainstem glioma (DBSG) who receive combination antineoplaston therapy [Antineoplastons A10 (Atengenal) & AS2-1 (Astugenal)] plus radiation therapy (RT) versus RT alone

DBSG are considered to be 1 of most difficult types of cancer to treat

Combines highly malignant characteristics with very difficult location of brainstem

DBSG are inoperable because they involve most of brainstem (diffuse & intrinsic)

# of children in U.S. with brainstem gliomas is approximately 660

Absent treatment, survival rate from time of diagnosis is 6 months or less

At present, no standard curative treatments for disease

RT is only treatment that may slow its progress, but at 2 years 93% of children with this type of cancer die, & none of them survive for 5 years

Other conventional treatments such as chemotherapy have generally been tried in clinical trials but shown to be ineffective

There are no pharmacological treatments approved for DBSG at this time

Burzynski Research Institute, Inc. (OTCBB: BZYR) is biopharmaceutical company committed to developing treatment for cancer based on genomic & epigenomic principles

19 Phase II clinical trials
======================================
5/21/2009
http://co-codes.com/index.php?cik=0000724445
======================================
5/29/2009
http://www.wikinvest.com/stock/Burzynski_Research_Institute_(BZYR)/Introduction
——————————————————————
Currently conducted phase II
http://www.wikinvest.com/stock/Burzynski_Research_Institute_(BZYR)/Liquidity_Capital_Resources
2009, Phase II FDA-supervised clinical trials of Antineoplastons successfully came to a close
——————————————————————
5/29/2009
http://www.wikinvest.com/stock/Burzynski_Research_Institute_(BZYR)/Liquidity_Capital_Resources
======================================
5/31/2009 (7/15/2009) Form 10-Q
http://www.sec.gov/Archives/edgar/data/0000724445/000110465909043323/0001104659-09-043323-index.htm
12/2/2008 Company announced orphan drug designation of Antineoplastons A10 and AS2-1 was expanded to treatment of all gliomas
——————————————————————
5/31/2009 (7/15/2009) 10-Q
http://edgar.secdatabase.com/2086/110465909043323/filing-main.htm
——————————————————————
5/31/2009 (7/15/2009) 10-Q PDF:
http://pdf.secdatabase.com/2086/0001104659-09-043323.pdf
——————————————————————
5/31/2009
http://www.sec.gov/Archives/edgar/data/0000724445/000110465909043323/0001104659-09-043323-index.htm
======================================
8/31/2009 (10/15/2009) 10-Q
http://edgar.secdatabase.com/2782/110465909059014/filing-main.htm
——————————————————————
8/31/2009 (10/15/2009) 10-Q PDF:
http://pdf.secdatabase.com/2782/0001104659-09-059014.pdf
——————————————————————
8/31/2009
http://www.sec.gov/Archives/edgar/data/0000724445/000110465909059014/0001104659-09-059014-index.htm
======================================
11/30/2009 (1/14/2010) Form 10-Q

9/2004 Company announced FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for treatment of brainstem glioma

During 2008, FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for treatment of all gliomas
——————————————————————
11/30/2009 (1/14/2010) 10-Q
http://edgar.secdatabase.com/741/110465910001658/filing-main.htm
——————————————————————
11/30/2009
http://www.sec.gov/Archives/edgar/data/0000724445/000110465910001658/0001104659-10-001658-index.htm
——————————————————————
11/30/2009 (1/14/2010) 10-Q PDF:
http://pdf.secdatabase.com/741/0001104659-10-001658.pdf
======================================
� � � � � � � � � � � � � � � � �
======================================
2/28/2010 Form 10-K (6/1/2010)
http://www.sec.gov/Archives/edgar/data/0000724445/000110465910031825/0001104659-10-031825-index.htm
Orphan Drug Designation

9/7/2004 FDA granted “orphan drug” status to Company’s Antineoplastons under Orphan Drug Act of 1983

Company began Phase II clinical studies in 1994 with 4 studies

2/23/1996 FDA requested that all then-current patients of Burzynski Clinic desiring to continue Antineoplaston treatment be admitted to Phase II Study, according to Protocol CAN-1
——————————————————————
2/28/2010
http://www.stocks-news.info/search/BZYR
——————————————————————
2/28/2010 (5/31/2010) 10-K
http://edgar.secdatabase.com/918/110465910031825/filing-main.htm
——————————————————————
2/28/2010
http://www.sec.gov/Archives/edgar/data/0000724445/000110465910031825/0001104659-10-031825-index.htm
——————————————————————
2/28/2010 (6/1/2010)10-K
http://pdf.secdatabase.com/918/0001104659-10-031825.pdf
======================================
5/31/2010 Form 10-Q (7/15/2010)
http://www.sec.gov/Archives/edgar/data/0000724445/000110465910038168/0001104659-10-038168-index.htm
9/2004 Company announced FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for treatment of brainstem glioma

2008 FDA awarded orphan drug status to Antineoplastons A10 and AS2-1 for the treatment of all glioma
http://www.sec.gov/Archives/edgar/data/0000724445/000110465910001658/0001104659-10-001658-index.htm

http://www.sec.gov/Archives/edgar/data/0000724445/000110465910038168/0001104659-10-038168-index.htm
2/1/2010 Company entered into agreement with Cycle Solutions, Inc., dba ResearchPoint

5 FDA-approved clinical trials
——————————————————————
5/31/2010 (7/15/2010) 10-Q
http://edgar.secdatabase.com/1263/110465910038168/filing-main.htm
——————————————————————
5/31/2010
http://www.sec.gov/Archives/edgar/data/0000724445/000110465910038168/0001104659-10-038168-index.htm
——————————————————————
5/31/2010 (7/15/2010) 10-Q PDF:
http://pdf.secdatabase.com/1263/0001104659-10-038168.pdf
======================================
8/31/2009 (10/15/2009) Form 10-Q
http://www.sec.gov/Archives/edgar/data/0000724445/000110465909059014/0001104659-09-059014-index.htm
——————————————————————
8/31/2010 (10/15/2010) 10-Q
http://edgar.secdatabase.com/541/110465910052441/filing-main.htm
——————————————————————
8/31/2010
http://www.sec.gov/Archives/edgar/data/0000724445/000110465910052441/0001104659-10-052441-index.htm
——————————————————————
8/31/2010 (10/15/2010) 10-Q PDF:
http://pdf.secdatabase.com/541/0001104659-10-052441.pdf
======================================
11/30/2010 (1/14/2012)
http://edgar.secdatabase.com/1977/110465911001561/filing-main.htm
——————————————————————
11/30/2010 (1/14/2011) 10-Q
http://pdf.secdatabase.com/1977/0001104659-11-001561.pdf
======================================
� � � � � � � � � � � � � � � � �
======================================
1/4/2011 (1/13/2009)
http://www.mystockbuddy.com/forum/archive/index.php/t-3959.html
======================================
2/28/2011 (5/31/2011) 10-K
http://edgar.secdatabase.com/2683/110465911032257/filing-main.htm
——————————————————————
2/28/2011 (5/31/2011) 10-K
http://www.sec.gov/Archives/edgar/data/0000724445/000110465911032257/0001104659-11-032257-index.htm
——————————————————————
2/28/2011 (5/31/2011) 10-K PDF:
http://pdf.secdatabase.com/2683/0001104659-11-032257.pdf
======================================
5/31/2011 (7/15/2011) 10-Q
http://pdf.secdatabase.com/704/0001104659-11-039275.pdf
——————————————————————
5/31/2011 10-Q
http://edgar.secdatabase.com/704/110465911039275/filing-main.htm
——————————————————————
5/31/2011 (7/15/2011) 10-Q
http://www.sec.gov/Archives/edgar/data/0000724445/000110465911039275/00011046/59-11-039275-index.htm
======================================
8/31/2011 (10/17/2011) 10-Q PDF:
http://pdf.secdatabase.com/2717/0001104659-11-056283.pdf
——————————————————————
8/31/2011 (10/17/2011) 10-Q
http://edgar.secdatabase.com/2717/110465911056283/filing-main.htm
——————————————————————
8/31/2011 (10/17/2011) 10-Q
http://www.sec.gov/Archives/edgar/data/0000724445/000110465911056283/0001104659-11-056283-index.htm
======================================
9/8/2011 (9/12/2011) 8-K
http://edgar.secdatabase.com/682/110465911051249/filing-main.htm
——————————————————————
9/8/2011
http://www.sec.gov/Archives/edgar/data/0000724445/000110465911051249/0001104659-11-051249-index.htm
——————————————————————
9/8/2011 (9/12/2011) 8-K PDF:
http://pdf.secdatabase.com/682/0001104659-11-051249.pdf
======================================
10/18/2011
http://www.highbeam.com/doc/1P3-2487745501.html
======================================
11/30/2011 (1/17/2012) 10-Q PDF:
http://pdf.secdatabase.com/1739/0001104659-12-014985.pdf
——————————————————————
11/30/2011 (1/17/2012) 10-Q
http://edgar.secdatabase.com/1093/110465912002343/filing-main.htm
——————————————————————
11/30/2011
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912002343/0001104659-12-002343-index.htm
——————————————————————
11/30/2011
http://www.sec.gov/Archives/edgar/data/0000724445/000110465911001561/0001104659-11-001561-index.htm
======================================
� � � � � � � � � � � � � � � � �
======================================
1/14/2012 10-Q
http://www.burzynskiresearch.com/sec-fillings.html
======================================
2/29/2012 Form 10-Q
(as of May 1, 2012) Protocol BT
http://www.sec.gov/Archives/edgar/data/724445/000110465912040430/a12-12972_110k.htm
——————————————————————
2/29/2012 (5/29/2012) 10-K PDF
http://pdf.secdatabase.com/193/0001104659-12-040430.pdf
——————————————————————
2/29/2012 (4/12/2012) 5 PDF:
http://pdf.secdatabase.com/2755/0001104659-12-024998.pdf
——————————————————————
2/29/2012 (4/12/2012) 5 PDF:
http://pdf.secdatabase.com/2754/0001104659-12-024997.pdf
——————————————————————
2/29/2012 (4/12/2012) 5 PDF:
http://pdf.secdatabase.com/2752/0001104659-12-024995.pdf
——————————————————————
2/29/2012 (4/12/2012) 5 PDF:
http://pdf.secdatabase.com/2751/0001104659-12-024994.pdf
——————————————————————
2/29/2012 (4/12/2012) 5 PDF:
http://pdf.secdatabase.com/2750/0001104659-12-024993.pdf
——————————————————————
2/29/2012 (4/12/2012) 5 PDF:
http://pdf.secdatabase.com/2749/0001104659-12-024992.pdf
——————————————————————
2/29/2012 (4/12/2012) 5 PDF:
http://pdf.secdatabase.com/2748/0001104659-12-024991.pdf
——————————————————————
2/29/2012 (3/1/2012) 8-K PDF:
http://pdf.secdatabase.com/1739/0001104659-12-014985.pdf
——————————————————————
2/29/2012 10-K
http://edgar.secdatabase.com/193/110465912040430/filing-main.htm
——————————————————————
2/29/2012 (4/12/2012) 5
http://edgar.secdatabase.com/2755/110465912024998/filing-main.htm
——————————————————————
2/29/2012 (4/12/2012) 5
http://edgar.secdatabase.com/2754/110465912024997/filing-main.htm
——————————————————————
2/29/2012 (4/12/2012) 5
http://edgar.secdatabase.com/2752/110465912024995/filing-main.htm
——————————————————————
2/29/2012 (4/12/2012) 5
http://edgar.secdatabase.com/2751/110465912024994/filing-main.htm
——————————————————————
2/29/2012 (4/12/2012) 5
http://edgar.secdatabase.com/2750/110465912024993/filing-main.htm
——————————————————————
2/29/2012 (4/12/2012) 5
http://edgar.secdatabase.com/2749/110465912024992/filing-main.htm
——————————————————————
2/29/2012 (4/12/2012) 5
http://edgar.secdatabase.com/2748/110465912024991/filing-main.htm
——————————————————————
2/29/2012 (3/1/2012) 8-K
http://edgar.secdatabase.com/1739/110465912014985/filing-main.htm
——————————————————————
2/29/2012 (5/29/2012) 10-K
Form 10-K (For the fiscal year ended February 29, 2012)
http://www.sec.gov/Archives/edgar/data/724445/000110465912040430/a12-12972_110k.htm
——————————————————————
2/29/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912040430/0001104659-12-040430-index.htm
——————————————————————
2/29/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912024998/0001104659-12-024998-index.htm
——————————————————————
2/29/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912024997/0001104659-12-024997-index.htm
——————————————————————
2/29/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912024995/0001104659-12-024995-index.htm
——————————————————————
2/29/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912024994/0001104659-12-024994-index.htm
——————————————————————
2/29/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912024993/0001104659-12-024993-index.htm
——————————————————————
2/29/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912024992/0001104659-12-024992-index.htm
——————————————————————
2/29/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912024991/0001104659-12-024991-index.htm
——————————————————————
2/29/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912014985/0001104659-12-014985-index.htm
——————————————————————
2/29/2012 (5/29/2012) 10-K
http://yahoo.brand.edgar-online.com/Default.aspx?companyid=45397&formtypeID=7
======================================
5/31/2012 (7/16/2012) 10-Q PDF:
http://pdf.secdatabase.com/2888/0001104659-12-049123.pdf
——————————————————————
5/31/2012 (7/16/2012) 10-Q
http://edgar.secdatabase.com/2888/110465912049123/filing-main.htm
——————————————————————
5/31/2012 10-Q
http://www.sec.gov/Archives/edgar/data/724445/000110465912049123/a12-16255_110q.htm
——————————————————————
5/31/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912049123/0001104659-12-049123-index.htm
——————————————————————
5/31/2012
http://yahoo.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=8718635-28809-40610&SessionID=2RB8FHhot2vqUu7
======================================
6/12/2012
http://investing.businessweek.com/research/stocks/financials/secfilings.asp?ticker=BZYR
======================================
7/5/2012 (7/6/2012) 8-K
http://www.secinfo.com/d11MXs.p1fVc.9.htm
——————————————————————
7/5/2012 (7/6/2012) 8-K PDF
http://pdf.secdatabase.com/1692/0001104659-12-047927.pdf
——————————————————————
7/5/2012 8-K
http://edgar.secdatabase.com/1692/110465912047927/filing-main.htm
——————————————————————
7/5/2012 (7/6/2012) 8-K
http://www.sec.gov/Archives/edgar/data/724445/000110465912047927/a12-16018_18k.htm
——————————————————————
7/5/2012
http://www.sec.gov/Archives/edgar/data/724445/000110465912047927/a12-16018_1ex10d10.htm
——————————————————————
7/5/2012 8k
http://marketbrief.com/bzyr/8k/events-or-changes-between-quarterly-reports/2012/7/6/9581961/filing
——————————————————————
7/5/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912047927/0001104659-12-047927-index.htm
======================================
8/31/2012 (10/15/2012)
Form 10-Q (Received 10/15/12 • Period 08/31/12)
“The Company believes Antineoplastons are useful in the treatment of human cancer and is currently conducting PHASE II CLINICAL TRIALS of Antineoplastons relating to the treatment of cancer”
——————————————————————
8/31/2012 10-Q
http://www.secinfo.com/d11MXs.p23hz.htm
——————————————————————
8/31/2012 10-Q
http://www.secinfo.com/d11MXs.p23hz.9.htm
——————————————————————
8/31/2012 (10/15/2012) 10-Q PDF
http://pdf.secdatabase.com/1939/0001104659-12-069167.pdf
——————————————————————
8/31/2012 10-Q
http://edgar.secdatabase.com/1939/110465912069167/filing-main.htm
——————————————————————
8/31/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465912069167/0001104659-12-069167-index.htm
======================================
10/15/2012 10-Q
http://biz.yahoo.com/e/121015/bzyr10-q.html
——————————————————————
10/15/2012 (8/31/2012) 10-Q
http://www.faqs.org/sec-filings/121015/BURZYNSKI-RESEARCH-INSTITUTE-INC_10-Q/R8.htm
======================================
11/30/2012 (1/14/2013)
Form 10-Q (For the quarterly period ended November 30, 2012) (1/14/2013)
http://www.faqs.org/sec-filings/130114/BURZYNSKI-RESEARCH-INSTITUTE-INC_10-Q
ONE FDA-approved CLINICAL TRIAL
——————————————————————
11/30/2012 Form 10-Q
http://www.secinfo.com/d11MXs.x28c.9.htm
——————————————————————
11/30/2012 10-Q PDF
http://pdf.secdatabase.com/2390/0001104659-13-002307.pdf
——————————————————————
11/30/2012 10-Q
http://edgar.secdatabase.com/2390/110465913002307/filing-main.htm
——————————————————————
11/30/2012 (1/14/2013) 10-Q
http://www.secdatabase.com/CIK/724445/Company-Name/BURZYNSKI-RESEARCH-INSTITUTE-INC
——————————————————————
11/30/2012
http://www.sec.gov/Archives/edgar/data/0000724445/000110465913002307/0001104659-13-002307-index.htm
======================================
� � � � � � � � � � � � � � � � �
======================================
2013
http://www.investorguide.com/stock-events.php?ticker=BZYR
——————————————————————
2013
http://yahoo.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=9017485-44747-46359&SessionID=WQ1HFHPq9Tdt6z7
======================================
1/14/2013
http://biz.yahoo.com/e/130114/bzyr10-q.html
======================================
2/28/2013 (5/29/2013) Form 10-K
http://www.sec.gov/Archives/edgar/data/724445/0001104659-13-045361-index.htm
======================================
5/29/2013 Form 10-K
http://biz.yahoo.com/e/130529/bzyr10-k.html
——————————————————————
5/29/2013 Form 10-K
http://www.faqs.org/sec-filings/130529/BURZYNSKI-RESEARCH-INSTITUTE-INC_10-K/
======================================
7/8/2013 (and prior)
http://marketbrief.com/bzyr/8k
——————————————————————
7/15/2013
http://www.crmz.com/EdgarFilingsCRM.asp?BusinessId=5337013
——————————————————————
7/15/2013 (and prior)
http://marketbrief.com/bzyr/10q
——————————————————————
7/15/2013 (and prior)
http://yahoo.brand.edgar-online.com/default.aspx?companyid=45397
======================================
� � � � � � � � � � � � � � � � �